Satralizumab, previously known as the SA-237 molecule, represents a significant treatment for NMOSD and other inflammatory ailments. Latest clinical trials have shown encouraging data regarding its https://bookmarks-hit.com/story25608999/satralizumab-a-deep-dive-into-sa-237-s-research-development